Aslan004 2b：若2022年中將亞獅康的市值帶上10億美金
若2022年中將亞獅康的市值帶上10億美金
ASLAN0042b每組收案人數(56-59人)比Lebrikizumab(73-80人)少17-21人.ASLAN0042b收案IGA3/4比59/41(比Lebrikizumab70/30嚴重些)ASLAN0042b基線四組平均EASI ...。其他文章還包含有：「AdultsWithModeratetoSevereAtopicDermatitis」、「ASLANPharmaceuticalsinitiatesPhase2bstudyof...」、「ASLANPharmaceuticalsInitiatesPhase2bStudyofASLAN004...」、「InvestorRelations」、「News&Publications」、「Phase2bStudyofASLAN0...
查看更多 離開網站
Adults With Moderate to Severe Atopic Dermatitis
https://www.clinicaltrials.gov
沒有這個頁面的資訊。
ASLAN Pharmaceuticals initiates Phase 2b study of ...
https://nationaleczema.org
ASLAN Pharmaceuticals initiates Phase 2b study of ASLAN004 (eblasakimab) in moderate-to-severe atopic dermatitis. Press Releases. By Lauren ...
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 ...
https://www.bloomberg.com
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis o The TRials with EblasaKimab in Atopic ...
Investor Relations
https://ir.aslanpharma.com
ASLAN Pharmaceuticals Initiates Phase 2b Study of ASLAN004 (Eblasakimab) in Moderate-to-Severe Atopic Dermatitis. The TRials with EblasaKimab ...
News & Publications
https://aslanpharma.com
ASLAN Pharmaceuticals initiates Phase 2b study of ASLAN004 (eblasakimab) in moderate-to-severe atopic dermatitis ... ASLAN Pharmaceuticals (Nasdaq: ASLN) has ...
Phase 2b Study of ASLAN004 in Adults With Moderate
https://classic.clinicaltrials
Phase 2b study designed to evaluate the efficacy and safety of ASLAN004 in adult patients with moderate-to-severe Atopic Dermatitis (AD) who are candidates for ...